Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human Adiponectin/Acrp30 Antibody, R&D Systems™

Mouse Monoclonal Antibody has been used in 4 publications
Supplier: R&D Systems MAB10651500
This item is not returnable.
View return policy
Description
Adiponectin/Acrp30 Monoclonal specifically detects Adiponectin/Acrp30 in Human samples. It is validated for ELISA Capture (Matched Antibody Pair).Specifications
Adiponectin/Acrp30 | |
Monoclonal | |
LYOPH | |
ELISA Capture (Matched Antibody Pair) 2-8 ug/mL | |
Q15848 | |
ADIPOQ | |
Mouse myeloma cell line NS0-derived recombinant human Adiponectin Glu19-Asn244 Accession # Q15848 | |
500 μg | |
Primary | |
Detects an epitope in the globular domain (aa 104 - 244) of human Adiponectin. In ELISAs, this antibody shows no cross-reactivity or interference with recombinant mouse (rm) Adiponectin or rh6Ckine. | |
Human | |
Supernatant |
ELISA | |
166126 | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
ACDC, Acrp30, ACRP30ADPN, adipocyte, C1Q and collagen domain containing, adiponectin, adiponectin, C1Q and collagen domain containing, AdipoQ, ADIPQTL1, apM-1, ApM1, APM1APM-1, C1q and collagen domain-containing protein, GBP28, GBP28apM1, Gelatin-binding protein | |
Mouse | |
Protein A or G purified from hybridoma culture supernatant | |
RUO | |
9370 | |
Reconstitute at 0.5 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
IgG2b |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction